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With the advance in personalized therapeutic strategies in patients with breast cancer, there is an 
increasing need for biomarker-guided therapy. Although the immunogenicity of breast cancer has 
not been strongly considered in research or practice, tumor-infiltrating lymphocytes (TILs) are 
emerging as biomarkers mediating tumor response to treatments. Earlier studies have provided 
evidence that the level of TILs has prognostic value and the potential for predictive value, particu-
larly in triple-negative and human epidermal growth factor receptor 2–positive breast cancer. 
Moreover, the level of TILs has been associated with treatment outcome in patients undergoing 
neoadjuvant chemotherapy. To date, no standardized methodology for measuring TILs has been 
established. In this article, we review current issues and clinical evidence for the use of TILs in 
breast cancer.
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Molecular medicine has shown that all cancers are caused by 
mutations accumulated in various genes. Cancerous tissues har-
boring genetic mutations frequently create a new class of tumor-
specific antigens.1,2 The presentation of neoantigen by tumor 
cells induces an immune response and triggers antitumor im-
munity. These neoantigens are displayed on the surfaces of tumor 
cells and are increased in relation to mutational load because 
mutations increase the efficiency with which a peptide is pre-
sented by MHC molecules.1 Recent findings based on whole-
exome sequencing have revealed that different tumors have dif-
ferent mutational loads, suggesting that neoantigen repertoire 
varies according to tumor type.3 That study showed that breast 
cancer has an average of one somatic mutation per megabase (Mb) 
of coding DNA and is expected to have moderate immunoge-
nicity among human cancers. 
Though the immunogenicity of breast cancer has not been 
traditionally considered in clinical practice or cancer research, 
the presence of tumor-infiltrating lymphocytes (TILs) in the tu-
mor or peritumoral site has emerged as a biomarker of antitu-
mor immune response in breast cancer. Despite the heterogene-
ity of TILs and the absence of a standardized methodology of 
evaluating TILs, recent studies have suggested that the presence 
of TILs is correlated with good outcome in patients with breast 
cancer.4-7 With advances in understanding of the role of the im-
mune system during carcinogenesis and tumor progression, TILs 
have been recognized as important biomarkers reflecting anti-
tumor immune response in several malignancies, such as epithe-
lial ovarian carcinoma8,9 and endometrial cancer,10-14 as well as 
breast cancer. 
Recent achievements in immune therapy such as adoptive T-
cell therapy or dendritic cell therapy, which reactivate the anti-
tumor immune response and immune check-points inhibiting 
monoclonal antibodies, have been applied in practice and have 
ameliorated outcomes in patients with advanced malignancies.15 
Understanding the biology and clinical utilization of TILs might 
offer novel therapeutic options in management of breast cancer. 
In this article, we review three issues of TILs in patients with 
breast cancer: (1) biology of TILs, (2) methodology defining TILs, 
and (3) clinical evidence of TILs as biomarkers with clinical 
utility.
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THE BIOLOGY OF TUMOR-INFILTRATING  
LYMPHOCYTES IN BREAST CANCER
The components of TILs
Infiltrating immune cells are frequently observed in tumors, 
but the proportion of immune cells comprising the host im-
mune system is diverse and depends on the type and organ sites 
of malignancies.16 Previous evidence from animal and clinical 
studies has shown that leukocyte subsets predominantly con-
tribute to either tumor-suppressive or tumor-stimulating activ-
ities. In murine models, myeloid lineage leukocytes, such as 
dendritic cells, myeloid-derived suppressor cells, and tumor-as-
sociated macrophages, have been identified and are thought to 
principally act to modulate the immune microenvironment to-
ward either an antitumor milieu or a tumor-promoting milieu. 
T cells that migrate to tumor and/or peritumor sites are activated 
or inactivated and, in turn, regulate macrophage differentiation 
via polarization toward pro-tumorigenic M2 or antitumor M1 
functional phenotypes, suggesting the importance of cell-to-cell 
cross-talk in the immune milieu.17
Most TILs are T lymphocytes.18-20 Tumor-infiltrating B lym-
phocytes are less common and are poorly defined.21 The compo-
sition of TILs has been well studied in two recent publications.19 
These studies showed similar results that T lymphocytes consti-
tuted 75% of TILs, B lymphocytes made up fewer than 20%, 
monocytes constituted fewer than 10%, and natural killer and 
natural killer T cells made up fewer than 5% of all leukocytes. 
To understand the role of T-lymphocyte–dominant TILs in 
antitumor response through adaptive immunity, it is necessary 
to understand the biologic characteristics and sub-classification 
of T cells. T cells, which are distinguished from other lympho-
cytes such as B cells and natural killer cells, have a T-cell recep-
tor on the cell surface. There are several subgroups of T lym-
phocytes, each with a unique function. CD8+ T cells are known 
as cytotoxic T cells and destroy tumor cells by binding to anti-
gen presented by MHC class I molecules, which are expressed 
on the membranes of all nucleated cells. These cytotoxic CD8+ 
T cells are regulated and can be inactivated by regulatory T 
cells (Treg), interleukin (IL) 10, and other cytokines, which pre-
vent autoimmune diseases. 
T helper cells (Th cells), which are also known as CD4+ T 
cells, mediate the immune response of other white blood cells. 
They assist in maturation of B cells into plasma cells and memo-
ry B cells and activate CD8+ T cells and macrophages. Th cells 
are activated when they come into contact with peptide antigens 
expressed by MHC class II molecules, which exist on the sur-
faces of antigen-presenting cells (APCs). This type of immune 
reaction is classified as type II immunity, which is distinguished 
from type I immunity, which is mainly conveyed by CD8+ T 
cells.22 When Th cells are activated, they undergo rapid division 
and release cytokines mediating the active immunologic reac-
tion. According to signaling from APCs, Th cells differentiate 
into various types such as Th1, Th2, Th3, Th17, Th9, or tu-
mor-infiltrated follicular helper (Tfh) and release different cyto-
kines to promote various active immune reactions. Among Th 
cells, Treg cells develop either in the thymus or in peripheral 
lymphoid organs. Treg cells developed in a peripheral lymphoid 
organ regulate adaptive immune responses.23 The expression of 
forkhead box P3 protein (FOXP3) is used to identify Treg cells. 
Several studies have highlighted the importance of T cells and 
TILs in breast cancer. Regarding the prognostic effect of cyto-
toxic CD8+ T cells, it is evident that the presence of these cells is 
significantly associated with prolonged survival outcome5,24 and 
good response to chemotherapy.25 The presence of CD8+ T cells 
is also associated with different subtypes of breast cancer. In a 
study with more than 1,200 breast cancer cases, high level of 
CD8+ T cells was found in the less aggressive subtypes, such as 
luminal cancer. In contrast, low level of CD8+ T cells was ob-
served in HER2-positive or basal-like breast cancer.26 
In contrast to the studies with CD8+ T cells, the prognostic 
effect of CD4+ T cells in breast cancer is variously reported and 
remains inconclusive. Th1 cells, which are the primary sources 
of interferon-γ, were reported to correlate with favorable prog-
nostic outcome,19 whereas Th2 cells were reported to counteract 
Th1 cells and attenuate the antitumor response based on analy-
ses with immune-gene signatures.27 A recent study defined the 
existence of Tfh cells and showed that an increase in CXCL13-
producing Tfh cells in tertiary lymphoid structures adjacent to 
breast tumors is positively associated with treatment outcome 
and might modulate an effective and durable antitumor im-
mune response.19 Th17 cells also contribute to the tumor micro-
environment. Particularly, the balance between Th17 cells and 
IL-17 family, which have pro-inflammatory functions, has an im-
portant role in regulating tumor angiogenesis. The effect of Th17 
cells near tumors seems to be variable depending on the cyto-
kine milieu.28 The antitumor or pro-tumor effect of Th17 cells 
might be different depending on the type of tumor.28 
Studies with CD4+ Treg cells expressing FOXP3 remain con-
troversial because the presence of Treg cells has been associated 
with both immunosuppressive and immunostimulatory activi-
ty.18,29,30 The effects of Treg cells on prognosis differed according 
to immunohistochemistry (IHC) marker and type of CD4+ T 
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cells. Interestingly, the ratio of CD8+ to FOXP3+ is correlated 
with molecular subtype26 and is characterized to define medul-
lary cancer.31 Furthermore, a recent study showed that this ratio 
can be used to identify patients with good response to neoadju-
vant chemotherapy in triple-negative breast cancer (TNBC).32
Currently, little is known regarding the role of tumor-infil-
trating B cells (CD20+) as components of TILs.33,34 Some au-
thors have reported that increased expression of immunoglobu-
lin κC by B cells is associated with favorable prognosis of breast 
cancer according to the database of gene-expression profiling.35
Factors affecting recruitment of TILs
There are several factors responsible for lymphocyte recruit-
ment in tumors. High endothelial venules (HEV) interact with 
blood vessels and contribute to lymphocyte infiltration in breast 
cancer.36 The high density of HEV is related to lymphotoxin-β 
produced by mature dendritic cells37 and is associated with im-
proved survival outcome in patients with breast cancer. It has 
been noted that HEV density is increased in ductal carcinoma 
in situ compared to invasive ductal carcinoma. 
Indoleamine-2,3-dioxygenase (IDO), which catalyzes the 
conversion of tryptophan to kynurenine, is one of the enzymes 
affecting lymphocytic infiltration of tumors. Tryptophan deple-
tion inhibits both tumor cells and lymphocytes, and kynurenine 
has cytotoxic activity against tumors.38 Therefore, the catalytic 
activity of IDO might inhibit or stimulate both tumor growth 
and antitumor immune functions.39
Factors affecting TIL count and recruitment of TILs have been 
studied. High TIL count has been observed in patients with 
TNBC.25 The presence of TILs has been shown to inversely cor-
relate with expression of human leukocyte antigen-G, which 
might be involved in tumor escape.40 The TIL count has also 
been reported to be associated with expression of stem cell mak-
ers or epithelial-mesenchymal transition markers in cancer cells.25
Stromal TILs and intratumoral TILs
Depending on lymphocyte-infiltrated site, TILs are classified 
as infiltrated lymphocytes in the tumor stroma (stromal TILs) 
or in the tumor cell islets (intratumoral TILs). Stromal TILs are 
defined as lymphocytes dispersed in the stroma and are distin-
guished from intratumoral TILs, which are located within car-
cinoma nests and are in direct contact with tumor cells.41 To date, 
most clinical trials have suggested that stromal TILs are likely 
to be more stable and reproducible markers than intratumoral 
TILs because of their increased frequency. 
 
Efforts in methodological agreement in evaluation of TILs in 
breast cancer
There are many hurdles to utilizing TILs as prognostic or pre-
dictive markers because of their heterogeneity and the absence 
of standardized methods of evaluation. Moreover, the method-
ology based on IHC assessment of TILs demonstrates enormous 
variation in analytical practice and limits the value of TIL mea-
surement to experimental research or specific studies. Conse-
quently, TIL determination is not yet feasible in routine clinical 
practice and urgently demands a consensus in the development 
of a standardized measurement system.
The initial method for measuring TILs was proposed by 
Denkert et al. in 2010,42 which evaluated TILs in specimens 
from core biopsies. Since then, the majority of researchers inves-
tigating TILs have used that method, which has now been sup-
ported by robust findings. With this background, an International 
TIL Working Group was recently organized, and participants 
with experience in evaluation of TILs in specimens from phase 
III clinical trials were surveyed regarding topics in the method-
ology of TILs evaluation. Consequently, they reported current 
recommendations to reconcile the method of evaluating TILs 
(Table 1).43 
Clinical evidence of TILs in adjuvant or neoadjuvant studies
Major adjuvant or neoadjuvant studies testing TILs are pre-
sented in Tables 2 and 3.5,24,25,35,41,42,44-57 Most of these studies 
evaluated both stromal and intratumoral TILs. As described 
above, the measurement of stromal TILs is more reproducible 
among studies and has superior clinical value. Some studies have 
evaluated TILs using IHC, whereas others have identified the 
immune components of TILs based on databases of gene-expres-
sion profiling. 
In 2010, the clinical significance of TILs as biomarkers associ-
ated with pathologic response was identified by Denkert et al.42 
using samples from large clinical trials. This pivotal study was 
the first to evaluate TILs using the protocol of the International 
TIL Working Group. From that time, many researchers have 
focused on the association between presence of TILs and clinical 
outcome in various cohorts. 
Among these translational studies with TILs in the adjuvant 
setting, the most important finding is the prognostic value of 
stromal TILs in TNBC. The positive correlation between in-
crease of stromal TILs and survival outcome in TNBC was ini-
tially reported using data from the BIG 2-98 trial.45 This corre-
lation was validated in independent cohorts of two clinical 
trials.46 Interestingly, the level of TILs was not prognostic in 
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patients with estrogen receptor (ER)–positive cancer receiving 
adjuvant chemotherapy. Consequently, these findings suggest 
that stromal TILs can be utilized as prognostic markers in a 
subset of breast cancer such as TNBC but not in ER-positive 
breast cancer. Despite the reproducibility of TILs as prognostic 
markers for patients with TNBC, TILs should not be used as 
predictive markers for chemotherapy response because of the 
absence of data from patients with TNBC not treated with che-
motherapy.
The pronounced prognostic effect of TILs particularly in 
TNBC can be explained by the neoantigens described in the in-
troduction because TNBC has higher mutational load than do 
non-TNBC tumors.58 The higher mutational load of TNBC tu-
mors enhances immunogenicity and might result in increased 
TIL recruiting. 
Some studies have attempted to verify the prognostic signifi-
cance of TILs in patients with HER2-positive breast cancer 
treated with adjuvant trastuzumab. Recent data from the FIN-
HER study suggested that increased TILs are associated with 
better response to adjuvant trastuzumab. In the study, patients 
with TIL-predominant tumors showed a superior survival out-
come compared to patients with non-TIL–predominant tumors 
after adjuvant trastuzumab.4 Recently published data from the 
N9831 study, which tested the benefit of trastuzumab in HER2-
positive breast cancer, also showed that patients with immuno-
genic tumors defined by mRNA expression of immune genes 
had improved survival in response to trastuzumab treatments.59 
However, there are major caveats to the results of the FINHER 
trial. The number of patients was small (n = 209), and the prog-
nostic value of TILs was not confirmed in multivariate analysis. 
Moreover, based on the same samples from the N9831 study, 
Perez et al.50 demonstrated conflicting results. In exploratory 
analyses of TIL evaluation, stromal TILs were associated with 
improved relapse-free survival in patients treated with chemo-
therapy alone but were not shown to be associated with recur-
rence-free survival in patients treated with chemotherapy plus 
trastuzumab. 
Therefore, based on the current findings, the effect of TILs in 
mediating the response to adjuvant trastuzumab is not conclu-
sive. Despite the controversy regarding the role of TILs in re-
sponse to HER2-targeted therapy, previous studies have sug-
gested that TILs mediate the antitumor response of trastuzumab 
and have the potential to be predictive markers of trastuzumab 
response.4 
In addition to stromal TILs identified by hematoxylin and eo-
sin exam, several studies have shown the prognostic value of 
CD8+ intratumoral TILs in adjuvant settings. Furthermore, ge-
nomic data might accelerate the discovery of immune markers or 
Table 1. International TIL Working Group recommendations for assessing TILs in breast cancer
1)  TILs should be reported for the stromal compartment (=% stromal TILs). The denominator used to determine the % stromal TILs is the area of stromal  
tissue (i.e., area occupied by mononuclear inflammatory cells over total intratumoral stromal area), not the number of stromal cells (i.e., fraction of total 
stromal nuclei that represent mononuclear inflammatory cell nuclei).
2) TILs should be evaluated within the borders of the invasive tumor.
3) Exclude TILs outside of the tumor border and around DCIS and normal lobules.
4) Exclude TILs in tumor zones with crush artifacts, necrosis, regressive hyalinization as well as in the previous core biopsy site.
5) All mononuclear cells (including lymphocytes and plasma cells) should be scored, but polymorphonuclear leukocytes are excluded.
6) One section (4–5 μm, magnification × 200–400) per patient is currently considered to be sufficient.
7)  Full sections are preferred over biopsies whenever possible. Cores can be used in the pretherapeutic neoadjuvant setting; currently no validated  
methodology has been developed to score TILs after neoadjuvant treatment.
8) A full assessment of average TILs in the tumor area by the pathologist should be used. Do not focus on hotspots.
9)  The working group’s consensus is that TILs may provide more biological relevant information when scored as a continuous variable, since this will allow 
more accurate statistical analyses, which can later be categorized around different thresholds. However, in daily practice, most pathologists will rarely  
report for example 13.5% and will round up to the nearest 5%–10%, in this example thus 15%. Pathologist should report their scores in as much detail  
as the pathologist feels comfortable with.
10)  TILs should be assessed as a continuous parameter. The percentage of stromal TILs is a semiquantitative parameter for this assessment, for example, 
80% stromal TILs means that 80% of the stromal area shows a dense mononuclear infiltrate. For assessment of percentage values, the dissociated 
growth pattern of lymphocytes needs to be taken into account. Lymphocytes typically do not form solid cellular aggregates; therefore,  
the designation ‘100% stromal TILs’ would still allow some empty tissue space between the individual lymphocytes.
11)  No formal recommendation for a clinically relevant TIL threshold(s) can be given at this stage. The consensus was that a valid methodology is currently 
more important than issues of thresholds for clinical use, which will be determined once a solid methodology is in place. Lymphocyte predominant  
breast cancer can be used as a descriptive term for tumors that contain ‘more lymphocytes than tumor cells’. However, the thresholds vary between  
50% and 60% stromal lymphocytes.
Adopted from Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL, Penault-Llorca F, Perez EA, 
Thompson EA, Symmans WF, Richardson AL, Brock J, Criscitiello C, Bailey H, Ignatiadis M, Floris G, Sparano J, Kos Z, Nielsen T, Rimm DL, Allison KH, Reis-
Filho JS, Loibl S, Sotiriou C, Viale G, Badve S, Adams S, Willard-Gallo K, Loi S. The evaluation of tumor infiltrating lymphocytes (TILs) in breast cancer: recom-
mendations by an International TILs Working Group 2014, Ann Oncol 2015; 26: 259-71, with permission of Oxford University Press.43
TIL, tumor-infiltrating lymphocytes; DCIS, ductal carcinoma in-situ.
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immune signatures associated with TILs or treatment outcome. 
TILs have been evaluated in the samples of core biopsies from 
more than 3,000 patients receiving neoadjuvant chemotherapy. 
These studies used clinical information from prospective trials, 
as well as from single institutional cohorts. In an early study of 
a cohort of limited size, the numbers of intratumoral TILs de-
tected by CD3 expression were significantly higher in patients 
with pathological complete response (pCR).41 Patients who 
achieved pCR also had significantly higher dendritic cell (CD83+) 
counts in specimens of core biopsies. The potential of TILs as 
biomarkers predicting pCR was independently confirmed using 
much larger cohorts of patients enrolled in the GeparDuo and 
GeparTrio trials. These studies showed that the percentage of 
intratumoral TILs is an independent predictor of pCR.42 The 
studies investigating the role of TILs in patients undergoing 
neoadjuvant chemotherapy are summarized in Table 3. In sum-
mary, data of both histologically assessed TILs and molecular 
genetic signatures indicate that increased immune markers are 
related to higher pCR rates independent of other clinico-patho-
logical factors or type of chemotherapy. A recent meta-analysis 
of TILs in neoadjuvant studies also supported the hypothesis 
that higher TIL level is associated with higher pCR rate.60
CONCLUSION
 
Accumulating preclinical and clinical evidence supports the 
use of TILs as predictive and prognostic markers in breast can-
cer. However, it is essential to establish a standard definition of 
TILs and to develop a consensus for morphological evaluation 
of TILs before they can be applied in routine clinical practice. 
The heterogeneity of types and functions of lymphocytes and 
activating mechanisms demands molecular and functional char-
acterization of TILs in order to improve their value. The incor-
poration of other biomarkers in breast cancer, such as the re-
maining hurdle with interobserver variability in determination 
of Ki-67, suggests that a biomarker cannot be widely applied 
in daily practice until a standardized approach has been validat-
ed in multiple studies including prospective trials. Further sci-
entific research with TILs will offer unique insights and infor-
mation on the role of the immune systems in malignancy and 
in treatment response. 
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